Best treatment of refractory peri-anal fistula in crohn's disease:-: (A) Fistulectomy, (B) Infliximab, (C) Olasalizine, (D) Mesalamine
Answer is B. Infliximab is effective in CD patients with refractory perianal and enterocutaneous fistulas, with 68% response rate (50% reduction in fistula drainage) and a 50% complete remission rate. Reinfusion, typically every 8 weeks, is necessary to continue therapeutic benefits in many patients.